Actuarial Underwriting Firms in the Life Settlement Space

What a Life Expectancy Underwriter Actually Does

A life expectancy (LE) underwriting firm sits at the intersection of medicine and actuarial science. Its job is narrow but critical: given an insured person’s medical records, produce a statistical estimate of remaining lifespan, usually expressed as a median life expectancy in months, along with a full mortality curve showing the probability of death in each future year.

The process starts with records. The underwriting firm receives attending physician statements, hospital records, lab results, prescription histories, and sometimes pharmacy database pulls covering several years of the insured’s medical history. A medical underwriter, often a nurse or physician working alongside credentialed actuaries, reviews the file and identifies every condition that affects mortality: cardiovascular disease, cancer history, diabetes, COPD, cognitive decline, kidney function, and dozens of lesser factors including build, smoking status, and functional independence.

Those findings are then translated into numbers. Most firms use a debit-and-credit methodology layered on top of a base mortality table: health impairments add mortality debits, while favorable factors such as excellent functional status or strong family longevity add credits. The adjusted mortality multiplier is applied to the base table to produce the individualized survival curve.

The output is a formal report that a life settlement provider plugs directly into its pricing model. Because the report drives the discounted cash flow analysis that determines an offer, LE underwriting is often described as the pricing engine of the entire secondary market. Our companion article on life settlement pricing mechanics shows exactly where the LE number enters the math.

The Major Firms in the Space

The LE underwriting industry is small and specialized, with a handful of firms handling the bulk of institutional volume. Names that appear regularly in life settlement transactions include Fasano Associates, AVS Underwriting, ISC Services, 21st Services, and newer analytically driven entrants that apply data science techniques to mortality estimation. Some firms have consolidated under common ownership over the years, which is one reason buyers insist on reports from genuinely independent sources rather than two brands with one methodology.

What distinguishes one firm from another is methodology and philosophy:

• Medical-records-driven firms emphasize deep clinical review, with physicians weighing in on complex cases such as active cancers or neurological disease.
• Actuarially driven firms lean on large proprietary datasets of insured lives, calibrating their debits and credits against actual-to-expected mortality studies of their own past predictions.
• Data-science entrants experiment with predictive models built on prescription histories, claims data, and even non-traditional inputs, aiming to estimate longevity with less reliance on full medical file review.

No regulator certifies a single correct methodology. Instead, the market disciplines the firms: providers and the institutional investors behind them track each firm’s actual-to-expected results, and a firm whose insureds consistently outlive its estimates loses credibility and business. This feedback loop is imperfect, because mortality results take years to mature, but it is the primary quality control in the space.

Why Buyers Order Two Independent Reports

The standard practice in institutional life settlement transactions is to obtain at least two independent LE reports on every insured. This convention exists for three reasons.

First, LE estimation is genuinely uncertain. Two competent firms reviewing the same medical file can disagree by a year or more, because they weight impairments differently, use different base tables, and apply different judgment on ambiguous records. Averaging or blending two views reduces the impact of any one firm’s bias.

Second, investors demand it. The institutional capital that funds policy purchases, described in who buys life insurance policies, typically writes two-report requirements into its investment guidelines, and some funds require reports from specific approved firms. A provider that wants to sell or finance its portfolio must underwrite to those standards from the start.

Third, history taught the industry a hard lesson. In the early viatical era and again in the mid-2000s, some market participants relied on optimistic LE estimates that systematically understated longevity. When insureds lived longer than projected, investors earned poor returns and litigation followed. The GAO’s 2010 report on the life settlement market flagged life expectancy estimation as a core risk area, and the industry’s response was more independence, more conservatism, and more reports per case.

For the policyholder, the practical effect is time: obtaining records and completing two rounds of underwriting typically takes two to six weeks within the broader 60 to 120 day settlement process.

Inside the Methodology: Tables, Debits, and Credits

Understanding the mechanics helps demystify why offers vary. Most LE firms begin with a base mortality table, frequently derived from the Valuation Basic Table series published through the actuarial profession and regulatory bodies coordinated by the NAIC. These tables describe the mortality of insured populations by age, sex, and smoking status.

The individualized work happens in the adjustment layer:

• Debits raise expected mortality. A history of congestive heart failure, insulin-dependent diabetes with complications, or a recent cancer diagnosis each carries a debit load reflecting published clinical survival data and the firm’s proprietary experience.
• Credits lower expected mortality. Well-controlled conditions, excellent functional capacity, regular preventive care, and favorable lab trends can offset debits.
• Multipliers and flat extras convert the net debit position into a percentage of table mortality. An insured assessed at 250 percent of table mortality is expected to die at two and a half times the rate of a standard insured of the same age and sex.

The firm then runs the adjusted mortality rates through a survival model to produce the median LE and the full curve. Two subtleties matter. The median is not the mean: skewed survival curves mean half of insureds outlive the median, some by many years. And the curve’s shape matters as much as its midpoint, because premium costs accumulate every month the insured survives, which is why buyers price on the whole distribution, as explained in how life settlement value is calculated.

Underwriting Element	What It Is	Effect on a Settlement Offer
Base mortality table	Population-level death rates by age, sex, smoking status	Sets the starting curve before individual adjustments
Medical debits	Mortality loads for documented health impairments	Shorter estimated LE, generally higher offer
Credits	Offsets for well-managed health and favorable factors	Longer estimated LE, generally lower offer
Median life expectancy	Month at which survival probability crosses 50%	Headline number in the pricing model
Full mortality curve	Year-by-year probabilities of death	Drives premium projections and discounted cash flow
Second independent report	Separate firm, separate methodology, same records	Blended or averaged; reduces single-firm bias
Report age	Time since the report was issued	Reports beyond roughly 12 months usually require refresh

How LE Reports Translate into Offer Prices

The connection between an LE report and a settlement offer is direct and mechanical. A buyer builds a discounted cash flow model: projected premium payments go out each year the insured is expected to survive, the death benefit comes in weighted by the probability of death in each year, and the whole stream is discounted at the investor’s required rate of return. The LE report supplies the probabilities that drive every line of that model.

The sensitivity is striking. A shorter life expectancy means fewer expected premium payments and an earlier expected death benefit, both of which raise the policy’s present value and the offer. A longer LE does the opposite. This is why offers across the market typically land between 10 and 35 percent of face value, with the insured’s health status, and therefore the LE estimate, as the dominant variable, alongside premium structure and policy type.

It also explains several policyholder experiences that otherwise seem puzzling:

• Offers from different buyers differ partly because they weight the two LE reports differently or use different approved firms.
• Health changes change everything. A policyholder declined two years ago may receive meaningful offers after a significant diagnosis, which is why periodic policy appraisals can be worthwhile.
• Very healthy insureds may get no offers at all, because a long LE makes the premium stream outweigh the discounted death benefit.

None of this is arbitrary; it is arithmetic performed on the underwriter’s mortality curve.

Accuracy, Track Records, and the A-to-E Problem

The uncomfortable truth about life expectancy estimation is that it can only be graded in hindsight. Firms measure themselves with actual-to-expected (A/E) studies: comparing the deaths that actually occurred in a block of previously underwritten lives against the deaths their curves predicted. An A/E ratio near 100 percent indicates well-calibrated estimates; a ratio well below 100 percent means insureds are outliving the projections.

Historically, the industry has gone through calibration cycles. Periods of systematic underestimation of longevity, driven by medical advances such as improved cardiac care and cancer therapies, forced firms to lengthen their estimates, sometimes abruptly. These table revisions rippled through the market: portfolios priced on the old curves lost value overnight, and investors learned to stress-test LE assumptions rather than take them at face value.

For policyholders, the calibration story has two practical implications. First, modern LE reports tend to be conservative, meaning longer, than those of earlier eras, which moderates offers but makes the market more stable, a theme explored in the history of life settlements. Second, because firms update methodologies as medicine advances, an LE report is a snapshot with a shelf life. Most buyers treat reports older than about a year as stale and require fresh underwriting, one reason the settlement process cannot simply reuse paperwork from a prior attempt to sell.

Regulation and Oversight of LE Providers

Life expectancy underwriting occupies a lightly regulated corner of a heavily regulated market. Life settlement brokers and providers must be licensed under state statutes modeled on the NAIC Life Settlements Model Act, but the underwriting firms that supply LE reports are, in most states, not separately licensed as such. A few states have adopted registration or disclosure requirements for LE providers, and regulators have periodically debated whether formal oversight should expand.

What fills the gap is a mix of indirect regulation and market discipline:

• Privacy law. LE firms handle protected health information and must comply with federal health privacy rules and the authorizations the insured signs during the application.
• Investor due diligence. Institutional buyers audit LE firms’ methodologies, staffing, and A/E results before approving them, a private oversight regime that is often more demanding than statutory review.
• Disclosure obligations. In regulated transactions, the policyholder’s authorization governs who may access medical records, and state acts require disclosure of how the transaction works, including the role of medical review.

In New Jersey, transactions fall under the state’s viatical settlement statute enforced by the New Jersey Department of Banking and Insurance, which licenses the brokers and providers who commission LE reports even though it does not license the underwriting firms themselves. Policyholders concerned about how their medical data will be used should ask their broker exactly which firms will receive records and under what authorization.

What Policyholders Should Know Before Underwriting Begins

Because LE underwriting happens behind the scenes, policyholders are sometimes surprised by what it involves. A few practical points set expectations.

You will sign medical authorizations. The process cannot begin without HIPAA-compliant releases allowing brokers, providers, and their LE firms to obtain your records. Gathering records from multiple physicians is usually the slowest step, and responding quickly to record requests is the single best way a seller can shorten the timeline.

You cannot pick your own number. Policyholders sometimes hope a personal physician’s optimistic or pessimistic view will drive the estimate. It will not; buyers rely on the independent firms’ standardized analysis precisely because it removes advocacy from the equation.

Honesty is essential. Understating health problems does not help you; a shorter documented life expectancy generally produces a higher offer, the opposite of traditional insurance underwriting. Overstating illness, meanwhile, is fraud. Simply let the records speak.

The report is not a prognosis. A median LE of, say, 96 months is a statistical midpoint for pricing, not a prediction about you personally, and half of similarly situated insureds live longer. Sellers should never make life decisions based on an LE report.

Finally, remember that underwriting is only one gate. Eligibility screens still apply, generally age 65 or older, face value of $100,000 or more, and a policy in force at least two years, and the ultimate decision remains yours after reviewing offers, as outlined in our guide for seniors.

---

Frequently Asked Questions

What is a life expectancy report in a life settlement?

A life expectancy report is a formal document produced by an independent medical underwriting firm that estimates how long an insured person is statistically likely to live. It is based on a review of medical records and expressed as a median life expectancy in months plus a full year-by-year mortality curve. Buyers of life insurance policies use these reports as the central input in their pricing models, so the report is the single biggest driver of the offer a policyholder receives. Most transactions require two independent reports.

Which companies provide life expectancy underwriting for life settlements?

A small group of specialized firms dominates the field, including names such as Fasano Associates, AVS Underwriting, ISC Services, and 21st Services, alongside newer data-analytics entrants. Each uses its own blend of medical record review, actuarial tables, and proprietary mortality data. No single firm is officially designated by regulators; instead, institutional investors approve specific firms after auditing their methodologies and their track record of actual deaths versus predicted deaths.

Why do life settlement buyers require two life expectancy reports?

Because life expectancy estimation involves judgment, two competent firms can reach estimates that differ by a year or more on the same medical file. Requiring two independent reports reduces the influence of any single firm’s bias, satisfies the investment guidelines of the institutional capital funding most purchases, and reflects lessons from earlier market cycles when overly optimistic estimates hurt investors. The two-report standard adds two to six weeks to the process but produces more reliable pricing.

Does a shorter life expectancy mean a higher life settlement offer?

Generally yes. A shorter estimated life expectancy means the buyer expects to pay fewer years of premiums and receive the death benefit sooner, both of which increase the policy’s present value in a discounted cash flow model. That is why offers typically range from 10 to 35 percent of face value, with health status as the dominant variable. This is the reverse of traditional insurance underwriting, where poor health raises your cost; in the secondary market, documented health impairments raise your proceeds.

How accurate are life expectancy estimates in life settlements?

They are statistical estimates, not predictions, and accuracy can only be measured across large groups over many years. Firms grade themselves with actual-to-expected studies comparing predicted deaths against real outcomes, and the industry has historically gone through cycles where medical advances forced firms to lengthen their estimates. Modern reports tend to be more conservative than those from earlier eras. For any individual, the median estimate is simply a midpoint; roughly half of similar insureds live longer than the median.

Do I have to release my medical records to sell my life insurance policy?

Yes. The underwriting that supports a life settlement offer cannot happen without HIPAA-compliant authorizations allowing the broker, provider, and their life expectancy underwriting firms to obtain your medical records, typically covering the past several years. Gathering records from physicians is usually the slowest part of the 60 to 120 day process. Your authorization controls who receives the records, and reputable intermediaries will tell you exactly which underwriting firms will review your file.

Are life expectancy underwriting firms regulated?

Only lightly, compared with brokers and providers. State life settlement statutes based on the NAIC Life Settlements Model Act license the brokers and providers in a transaction, but most states do not separately license LE underwriting firms, though a few require registration. Oversight comes mainly from federal health privacy rules governing medical data and from institutional investors, who audit the firms’ methodologies and mortality track records before approving them for use in transactions they fund.

Can my own doctor’s opinion be used instead of an LE report?

No. Buyers rely exclusively on independent underwriting firms because standardized, arm’s-length analysis removes advocacy from pricing. Your physician’s records are essential raw material, and a detailed, current medical file helps the underwriters assess your situation accurately, but the estimate itself comes from the firm’s actuarial methodology. Policyholders should also remember the report is a pricing tool, not a medical prognosis, and should never treat it as a prediction about their personal lifespan.

Related Reading

• Independent Life Expectancy Reports
• Life Settlement Pricing Mechanics
• How Life Settlement Value Is Calculated
• Who Buys Life Insurance Policies

---

Pine Lake Life Solutions does not purchase life insurance policies and does not provide legal, tax, or investment advice. Information provided is for educational purposes only. Eligibility for any option, including life settlements, is not guaranteed and depends on individual circumstances, policy terms, underwriting, and market conditions. Consult independent legal, tax, or financial professionals before making decisions regarding a life insurance policy.